📰 Merck Sharp News
Page 82 - Merck Sharp News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Merck Sharp. Real-time updates on events, politics, business and more.
February 9, 2022
Keytruda treatment found to cut risk of aggressive cancer returning after surgery by more than a third
February 7, 2022
Ukraine has received the first batch of 60,000 courses of Molnupiravir for the treatment of COVID-19, Minister of Health Viktor Liashko wrote on Facebook. — Ukrinform.
February 3, 2022
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
February 3, 2022
On Wednesday, a case was filed in the District of Delaware by Acerta Pharma B.V., AstraZeneca Pharmaceuticals, and Merck Sharp & Dohme B.V. against
February 1, 2022
The recommendations strive to streamline vaccination, improve uptake.
January 28, 2022
10 Year Anniversary Event of the Public-Private Partnership "London Declaration"TOKYO, Jan 28, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that its CEO Haruo Naito participated in the online
January 28, 2022
TOKYO, Jan 28, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that its CEO Haruo Naito participated in the online event entitled "100% COMMITTED to End NTDs" celebrating the 10th anniversary of the London Declaration, an international public-private partnership to eliminate neglected tropical diseases (NTDs), on January 27, 2022. CEO Naito represented pharmaceutical companies and highlighted the achievements...
January 27, 2022
Taipei, Jan. 27 (CNA) Taiwan on Thursday received its first batch of Pfizer's COVID-19 treatment Paxlovid, as well as its final shipment of the Pfizer-BioNTech COVID-19 vaccine, according to the Central Epidemic Command Center (CECC).
January 25, 2022
/PRNewswire/ -- Cytovation AS, a clinical stage immune-oncology company focused on the development of its first-in-class targeted tumor membrane immunotherapy,...
January 25, 2022
/PRNewswire/ -- Cytovation AS, a clinical stage immune-oncology company focused on the development of its first-in-class targeted tumor membrane immunotherapy,...